Before propensity matching (N = 56,351) | After propensity matching (N = 36,898) | |||||
---|---|---|---|---|---|---|
n(%) / mean(±sd) | No T2DM | T2DM | P | No T2DM | T2DM | P |
Women | 24,495 | 13,299 | < 0.001 | 12,741 | 12,644 | 0.276 |
66.23 | 68.66 | 69.06 | 68.53 | |||
Age | 65.50 (+ − 13.66) | 63.24 (+ − 13.08) | < 0.001 | 63.7 (+ − 13.5) | 63.8 (+ − 13.0) | 0.7186 |
Hypertension | 36,444 | 17,998 | < 0.001 | 17,915 | 17,935 | 0.531 |
98.54 | 92.93 | 97.11 | 97.21 | |||
Dyslipidemia | 31,323 | 16,685 | < 0.001 | 15,956 | 15,983 | 0.680 |
84.7 | 86.15 | 86.49 | 86.63 | |||
Obesity | 14,323 | 9700 | < 0.001 | 9278 | 9315 | 0.700 |
38.73 | 50.08 | 50.29 | 50.49 | |||
Controlled Hypertension | 33,096 | 17,582 | < 0.001 | 16,652 | 16,702 | 0.377 |
89.49 | 90.78 | 90.26 | 90.53 | |||
CKD | 5440 | 3184 | < 0.001 | 3040 | 3034 | 0.933 |
14.71 | 16.44 | 16.48 | 16.45 | |||
Number of antihypertensive drugs | 0.72 (+ − 0.44) | 0.67 (+ − 0.46) | < 0.001 | 1.81(+ − 1.66) | 1.82(+ − 1.8) | 0.227 |
ACEI-ARB | 24,218 | 12,126 | < 0.001 | 12,075 | 12,072 | 0.974 |
65.48 | 62.61 | 65.45 | 65.43 | |||
Antiplatelet | 12,957 | 7492 | < 0.001 | 7242 | 7347 | 0.264 |
35.04 | 38.68 | 39.25 | 39.82 | |||
Calcium Antagonists | 9943 | 5878 | < 0.001 | 5776 | 5817 | 0.646 |
26.89 | 30.35 | 31.31 | 31.53 | |||
Statins | 15,624 | 9672 | < 0.001 | 9323 | 9382 | 0.539 |
42.25 | 49.94 | 50.53 | 50.85 | |||
Insulin | 0 | 3418 | < 0.001 | 0 | 3222 | < 0.001 |
0 | 17.65 | 0 | 17.46 | |||
Human Insulin | 0 | 1604 | < 0.001 | 0 | 1497 | < 0.001 |
0 | 8.28 | 0 | 8.11 | |||
Analogous Insulin | 0 | 2503 | < 0.001 | 0 | 2375 | < 0.001 |
0 | 12.92 | 0 | 12.87 | |||
Sulfonylureas | 0 | 5852 | < 0.001 | 0 | 5548 | < 0.001 |
0 | 30.21 | 0 | 30.07 | |||
Metformin | 0 | 8430 | < 0.001 | 0 | 7950 | < 0.0010 |
0 | 43.53 | 0 | 43.09 | |||
DPP4-I | 0 | 677 | < 0.001 | 0 | 648 | < 0.001 |
0 | 3.5 | 0 | 3.51 | |||
GLP1 receptor agonists | 0 | 88 | < 0.001 | 0 | 85 | < 0.001 |
0 | 0.45 | 0 | 0.46 |